Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Dermatology | Family Medicine | Pharmacy | Journal

Back to Journal Articles

Short/Long-Term Analyses Deem Etanercept Safe for Psoriasis

Last Updated: July 27, 2012.

 

No increase in cumulative or dose-related adverse events during short- or long-term treatment

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Etanercept treatment is well tolerated for psoriasis, with no indication of dose-related or cumulative toxicity in short- or long-term analyses, according to a study published in the August issue of the Journal of the American Academy of Dermatology.

FRIDAY, July 27 (HealthDay News) -- Etanercept treatment is well tolerated for psoriasis, with no indication of dose-related or cumulative toxicity in short- or long-term analyses, according to a study published in the August issue of the Journal of the American Academy of Dermatology.

David M. Pariser, M.D., of Virginia Clinical Research Inc. in Norfolk, and colleagues integrated safety data from short- and long-term etanercept psoriasis trials to determine whether higher doses or extended exposure to etanercept increases the safety risk.

The researchers found that the rate of infectious and noninfectious adverse events (AEs) did not differ significantly between etanercept and placebo treatment groups in short-term analyses (up to 12 weeks of treatment). No dose-related increases in AEs were noted with either short- or long-term (up to 144 weeks) etanercept treatment. Cumulative event rates for serious infections were not significantly different over time or between dose groups. There was no significant difference in the standardized incidence ratios for malignancies excluding nonmelanoma skin cancer. No increase in overall malignancies was noted with etanercept treatment. Congestive heart failure, lymphoma, demyelination, and opportunistic infection were all rare.

"These integrated short- and long-term analyses demonstrated that etanercept was generally well tolerated in a large population of patients with psoriasis without dose-related or cumulative toxicities," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: 'Bath Salts' Demonstrate High Potential for Abuse Next: Good Long-Term Limb Salvage for Diabetic Foot Patients

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.